Roche’s Virtual Event following Angiogenesis 2022
Agenda
Welcome
Ophthalmology franchise strategy
Ophthalmology clinical development
Angiogenesis highlights
Q&A
Bruno Eschli, Head of Investor Relations
Nilesh Mehta, Global Franchise Head, Ophthalmology
Christopher Brittain, Vice President and Global Head of Ophthalmology Product Development
2-Year data for Susvimo in nAMD (Ph III Archway), 2-Year data for Vabysmo in DME (Ph III YOSEMITE & RHINE), Nancy Holekamp, M.D., Retina Specialist

Please register to access the replay*

*Privacy notice

Roche has hosted a virtual event on Monday, 14 February 2021.

Live Webinar Replay

Investors
Past IR Events
View more Events

Downloads

Related links